|
1
|
Lekakis L, Tryfonopoulos D, Pistamatzian
N, et al: Salvage chemotherapy with cisplatin and 5-fluorouracil in
metastatic breast cancer. Particular activity against liver
metastases. Anticancer Res. 32:1833–1837. 2012.
|
|
2
|
García-Velasco A, Durán I, García E, et
al: Biological markers of cisplatin resistance in advanced
testicular germ cell tumours. Clin Transl Oncol. 14:452–457.
2012.
|
|
3
|
Yanagawa M, Tatsumi M, Miyata H, et al:
Evaluation of response to neoadjuvant chemotherapy for esophageal
cancer: PET response criteria in solid tumors versus response
evaluation criteria in solid tumors. J Nucl Med. 53:872–880.
2012.
|
|
4
|
Kumar A and Saba JD: Lyase to live by:
sphingosine phosphate lyase as a therapeutic target. Expert Opin
Ther Targets. 13:1013–1025. 2009.
|
|
5
|
Hla T: Physiological and pathological
actions of sphingosine 1-phosphate. Semin Cell Dev Biol.
15:513–520. 2004.
|
|
6
|
Ogretmen B and Hannun YA: Biologically
active sphingolipids in cancer pathogenesis and treatment. Nat Rev
Cancer. 4:604–616. 2004.
|
|
7
|
Spiegel S and Milstien S: Sphingosine
1-phosphate, a key cell signaling molecule. J Biol Chem.
277:25851–25854. 2002.
|
|
8
|
Taha TA, Argraves KM and Obeid LM:
Sphingosine-1-phosphate receptors: receptor specificity versus
functional redundancy. Biochim Biophys Acta. 1682:48–55. 2004.
|
|
9
|
Kumar A, Wessels D, Daniels KJ, et al:
Sphingosine-1-phosphate plays a role in the suppression of lateral
pseudopod formation during Dictyostelium discoideum cell migration
and chemotaxis. Cell Motil Cytoskeleton. 59:227–241. 2004.
|
|
10
|
Oskouian B and Saba JD: Death and taxis:
what non-mammalian models tell us about sphingosine-1-phosphate.
Semin Cell Dev Biol. 15:529–540. 2004.
|
|
11
|
Spiegel S, English D and Milstien S:
Sphingosine 1-phosphate signaling: providing cells with a sense of
direction. Trends Cell Biol. 12:236–242. 2002.
|
|
12
|
French KJ, Upson JJ, Keller SN, et al:
Antitumor activity of sphingosine kinase inhibitors. J Pharmacol
Exp Ther. 318:596–603. 2006.
|
|
13
|
Roukos DH and Kappas AM: Perspectives in
the treatment of gastric cancer. Nat Clin Pract Oncol. 2:98–107.
2005.
|
|
14
|
Menges M, Schmidt C, Lindemann W, et al:
Low toxic neoadjuvant cisplatin, 5-fluorouracil and folinic acid in
locally advanced gastric cancer yields high R-0 resection rate. J
Cancer Res Clin Oncol. 129:423–429. 2003.
|
|
15
|
Zhao Z, Wang J, Tang J, et al: JNK-and
Akt-mediated Puma expression in the apoptosis of
cisplatin-resistant ovarian cancer cells. Biochem J. 444:291–301.
2012.
|
|
16
|
Hasegawa M, Ishiguro K, Ando T and Goto H:
Geranylgeranylacetone attenuates cisplatin-induced reductions in
cell viability by suppressing the elevation of intracellular p53
content without heat shock protein induction. Nagoya J Med Sci.
74:123–131. 2012.
|
|
17
|
Vasconcelos FC, Cavalcanti GB Jr, Silva
KL, et al: Constrasting features of MDR phenotype in leukemias by
using two fluorochromes: implications for clinical practice. Leuk
Res. 31:445–454. 2007.
|
|
18
|
Patel NH and Rothenberg ML: Multidrug
resistance in cancer chemotherapy. Invest New Drugs. 12:1–13.
1994.
|
|
19
|
Legrand O, Simonin G, Beauchamp-Nicoud A,
et al: Simultaneous activity of MRP1 and Pgp is correlated with in
vitro resistance to daunorubicin and with in vivo resistance in
adult acute myeloid leukemia. Blood. 94:1046–1056. 1999.
|
|
20
|
Valko M, Rhodes CJ, Moncol J, et al: Free
radicals, metals and antioxidants in oxidative stress-induced
cancer. Chem Biol Interact. 160:1–40. 2006.
|
|
21
|
Cobb MH and Goldsmith EJ: How MAP kinases
are regulated. J Biol Chem. 270:14843–14846. 1995.
|
|
22
|
Wagner EF and Nebreda AR: Signal
integration by JNK and p38 MAPK pathways in cancer development. Nat
Rev Cancer. 9:537–549. 2009.
|
|
23
|
Lee HG, Minematsu H, Kim KO, et al: Actin
and ERK1/2-CEBPβ signaling mediates phagocytosis-induced innate
immune response of osteoprogenitor cells. Biomaterials.
32:9197–9206. 2011.
|
|
24
|
McGlynn LM, Kirkegaard T, Edwards J, et
al: Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not
chemotherapy in breast cancer patients. Clin Cancer Res.
15:1487–1495. 2009.
|
|
25
|
Atmaca A, Pauligk C, Steinmetz K, et al:
Prognostic impact of phosphorylated mitogen-activated protein
kinase expression in patients with metastatic gastric cancer.
Oncology. 80:130–134. 2011.
|
|
26
|
Wasserman WW and Fahl WE: Functional
antioxidant responsive elements. Proc Natl Acad Sci USA.
94:5361–5366. 1997.
|
|
27
|
Li Y and Jaiswal AK: Regulation of human
NAD(P)H: quinone oxidoreductase gene. Role of AP1 binding site
contained within human antioxidant response element. J Biol Chem.
267:15097–15104. 1992.
|
|
28
|
Rushmore TH and Pickett CB:
Transcriptional regulation of the rat glutathione S-transferase Ya
subunit gene. Characterization of a xenobiotic-responsive element
controlling inducible expression by phenolic antioxidants. J Biol
Chem. 265:14648–14653. 1990.
|
|
29
|
Prestera T, Holtzclaw WD, Zhang Y and
Talalay P: Chemical and molecular regulation of enzymes that
detoxify carcinogens. Proc Natl Acad Sci USA. 90:2965–2969.
1993.
|
